Every other mushroom on this site has the same interactions problem: almost no human cases, so the warnings are inference dressed up as caution. Amanita muscaria is the exception, and not in a comforting way. Its two active compounds have known receptor targets, which means the most important interaction here can be predicted from pharmacology rather than waited for. That's a stronger warning than the rest of the category can issue — and it's the one most product pages leave out.
Muscimol is a GABA-A receptor agonist, so combining Amanita muscaria with alcohol, benzodiazepines, z-drugs, gabapentinoids, barbiturates, opioids or sedating antihistamines carries an additive CNS-depression risk that follows from the mechanism, not from case reports. Ibotenic acid acts on glutamate receptors instead, producing the excitatory phase — and because drying converts ibotenic acid to muscimol, how a batch was processed changes which risk dominates. In a 15-year US poison-centre review of 34 cases, 25 patients were symptomatic, five were intubated, and no deaths occurred (Moss 2019).
We sell this mushroom. That makes the honest version of this page more useful than a reassuring one, so what follows includes the parts that don't help us sell it.
Why Are Amanita's Interactions Different From Every Other Mushroom Here?
Because we know what its compounds bind to. Reishi, lion's mane, chaga and the rest are polysaccharide-dominated materials whose interaction warnings rest on mechanism-by-analogy and, across the whole category, roughly three published human cases — as our interactions guide sets out.
Amanita muscaria is the opposite case. Ibotenic acid and muscimol are identified active components with described receptor activity, reviewed in detail by Michelot and Melendez-Howell in Mycological Research. When a compound is a known agonist at the receptor that sedatives act on, you don't need a case report to justify the warning.
That flips how you should read pages in this category. Elsewhere, a loud interaction warning often means somebody copied it. Here, a quiet page means somebody left something out.
What Does Muscimol Do, and What Does It Predict?
It agonises GABA-A receptors — the same inhibitory system that benzodiazepines, z-drugs, barbiturates and alcohol all act on, by different routes. Adding a direct agonist to any of those means stacking two things that suppress central nervous system activity.
The practical list of what shouldn't be combined follows straight from that:
- Alcohol — the most common real-world combination, and the one most likely to turn a manageable dose into a hospital visit.
- Benzodiazepines (diazepam, lorazepam, alprazolam) and z-drugs (zolpidem, zopiclone).
- Gabapentinoids (gabapentin, pregabalin) and barbiturates.
- Opioids, including codeine-containing painkillers.
- Sedating antihistamines such as diphenhydramine and promethazine.
- Muscle relaxants and general anaesthesia — tell your anaesthetist before surgery.
None of that is exotic. Several of those are over-the-counter in most of Europe, which is precisely why the combination happens by accident.
What Does Ibotenic Acid Do Differently?
It acts on glutamate receptors rather than GABA ones, which is the excitatory side of the same coin. In practice that's the agitation, disorientation, muscle twitching and nausea that show up early, before the sedative phase takes over.
So a single mushroom carries two opposing pharmacologies. Michelot and Melendez-Howell describe the resulting syndrome as central nervous system dysfunction rather than simple sedation, and that's the right frame: it isn't a sleeping aid with side effects, it's two compounds pulling in opposite directions.
Why the Same Product Interacts Differently Depending on How It Was Dried
Drying decarboxylates ibotenic acid into muscimol. A thoroughly dried, well-processed batch sits further toward the muscimol end; an underprocessed one carries more ibotenic acid. Both are sold as the same thing.
Follow that through and something uncomfortable appears. The interaction profile isn't a fixed property of the species — it's a property of the batch. A muscimol-dominant batch stacks harder with sedatives. An ibotenic-dominant batch produces more of the excitatory, nauseating presentation. Our chemistry article and drying guide cover the conversion; the consequence for interactions is rarely stated anywhere.
This is also why "start low with every new batch" is a safety instruction and not a sales line. Our potency factors article explains what else varies.
What Do the Documented Cases Actually Look Like?
Less dramatic than the internet suggests, and not trivial either. Moss and Hendrickson reviewed 15 years of ingestions reported to a US regional poison centre and found 34 cases meeting inclusion criteria — 23 Amanita muscaria, 10 A. pantherina, one A. aprica.
Twenty-five patients were symptomatic. All but one developed symptoms within six hours, and 15 had symptoms lasting under 24 hours. Five patients were intubated. Notably, no patient experienced hypotension, seizures, acute kidney injury or hepatotoxicity, and there were no deaths.
A. pantherina was consistently worse than muscaria: any GI symptoms in 80% versus 35%, CNS depression 70% versus 35%, CNS excitation 70% versus 35%. That gap is the reason the two species get separate advice, covered in our pantherina contraindications article.
The Muscarine Question Has Reopened
For decades the standard line was that muscarine in Amanita muscaria is negligible, based on a 1950s figure of 0.0003% in fresh mushrooms. Feeney's 2025 analysis in the International Journal of Medicinal Mushrooms challenges that directly.
The team collected surveys from 53 people who reported cholinergic symptoms after ingestion, then ran HPLC-MS/MS on samples. Mild-to-moderate cholinergic symptoms — salivation, sweating, tearing, gut cramping — appeared at 1 to 20 grams dried, which is squarely the range people actually use.
Why does that matter for interactions? Because it puts anticholinergic and cholinergic drugs back into the conversation, and because the symptoms people were dismissing as "part of the experience" may have a specific pharmacological cause. We used the same paper in our regalis comparison, where it cuts against one of our own product claims.
Interactions Ranked by How Much We Actually Know
| Combination | Basis | Strength of concern |
|---|---|---|
| Alcohol | Shared CNS depressant action; muscimol is a GABA-A agonist | Avoid entirely |
| Benzodiazepines, z-drugs, barbiturates | Same receptor system, direct additive effect | Avoid entirely |
| Opioids, gabapentinoids, sedating antihistamines | Additive CNS and respiratory depression | Avoid |
| General anaesthesia, muscle relaxants | Additive; disclose before any procedure | Tell your clinician |
| Cholinergic and anticholinergic drugs | Reopened by Feeney 2025 muscarine findings | Unsettled — caution |
| Antidepressants (SSRIs, SNRIs) | No published human case; no shared primary target | Unknown, not established |
| Anticoagulants | No mechanism, no case | No basis for concern |
Driving, Work and Machinery
Don't. A compound that agonises the receptor system targeted by prescription sedatives will impair reaction time and judgement, and the poison-centre data shows onset within six hours in almost every symptomatic case. Duration ran beyond 24 hours in some.
Worth stating plainly: in most jurisdictions, driving impaired is an offence regardless of whether the substance is legal there. Our legal status article covers the separate question of legality.
Who Should Avoid It Entirely
- Anyone pregnant or breastfeeding — ibotenic acid and muscimol are small molecules with no safety data in pregnancy. See our pregnancy article.
- Anyone taking any of the sedatives listed above, unless a prescriber has said otherwise.
- People with a seizure history. No seizures occurred in the Moss series, but glutamatergic activity makes this the wrong thing to experiment with.
- Anyone with significant liver or kidney impairment, on general clearance grounds.
- Under-18s. Two of the four symptomatic paediatric cases in the Moss review were accidental ingestions.
- Households with pets — dogs are frequent accidental casualties, covered in our pet safety article.
What About Tolerance and Stopping?
There's no withdrawal syndrome described in the literature for Amanita muscaria, and no controlled tolerance study either. Absence of published evidence isn't the same as evidence of absence, particularly for a GABA-A agonist — that's the receptor class where tolerance and rebound are best documented for other drugs. Our tolerance and cycling article takes the general case.
Frequently Asked Questions
Can you drink alcohol with Amanita muscaria?
No. Muscimol is a GABA-A receptor agonist and alcohol depresses the same system, so the effects add. This is the one interaction that follows directly from known pharmacology rather than from case reports, and it's also the most common real-world combination.
What are the most common side effects?
Nausea and vomiting, sweating and salivation, disorientation, drowsiness, and muscle twitching. In a 34-case poison-centre review, 25 patients were symptomatic, almost all within six hours, and most symptoms resolved inside 24 hours.
Has anyone died from Amanita muscaria?
Not in the 15-year US poison-centre series reviewed by Moss and Hendrickson, where five of 34 patients were intubated but none died. Fatalities are reported very rarely elsewhere. This is a mushroom that causes serious symptoms far more often than it causes deaths.
Does Amanita muscaria interact with antidepressants?
No published human case exists, and the compounds don't share a primary target with SSRIs or SNRIs. That's genuinely unknown territory rather than a documented risk — which is a reason for caution and a prescriber conversation, not a reason to assume safety.
Why do some batches make people sweat and salivate?
Possibly muscarine. Feeney's 2025 analysis found cholinergic symptoms reported at 1–20 grams dried and measured muscarine well above the long-assumed 0.0003%, reopening a question the field considered closed since the 1950s.
Shop Amanita muscaria
If you're going to use this mushroom, batch consistency and honest processing matter more than grade. Grade A caps (50 g €55, 100 g €79, 300 g €225) and Grade B (200 g €89, 400 g €159, 1 kg €349) come from the same Carpathian harvest. Capsules (120 caps €55) remove the weighing error that causes most accidental overdoses. Read the safety checklist before your first dose. Free shipping on orders over €50.
Related Articles
- Amanita muscaria Safety Checklist
- Symptoms of Amanita Poisoning
- Is Amanita muscaria Poisonous?
- Ibotenic Acid vs Muscimol
- How to Take Amanita muscaria
- Mushroom Supplements and Medication Interactions
- Amanita muscaria and Pets
Sources
- Moss MJ, Hendrickson RG. Toxicity of muscimol and ibotenic acid containing mushrooms reported to a regional poison control center from 2002-2016. Clin Toxicol (Phila). 2019;57(2):99-103. PubMed 30073844
- Michelot D, Melendez-Howell LM. Amanita muscaria: chemistry, biology, toxicology, and ethnomycology. Mycol Res. 2003;107(2):131-146. PubMed 12747324
- Feeney K, Kababick J, Wise S. An examination of cholinergic symptoms produced by the fly agaric mushroom Amanita muscaria (Agaricomycetes): revisiting the role of muscarine. Int J Med Mushrooms. 2025;27(7):1-15. PubMed 40228215
- Leas EC, Satybaldiyeva N, Kepner W, et al. Need for a public health response to the unregulated sales of Amanita muscaria mushrooms. Am J Prev Med. 2024;67(3):458-463. PubMed 38864780